To the full analysis
Buyback calculator for Sinopharm Group
Sinopharm Group stock: key metrics
1099.HKSinopharm Group had an operating margin of 2.8% and a return on invested capital (ROIC) of 7.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 8.4% | 2.0% | 0.8% |
| 2007 | 8.2% | 2.5% | 1.7% |
| 2008 | 7.9% | 3.1% | 2.1% |
| 2009 | 8.0% | 3.3% | 1.8% |
| 2010 | 8.4% | 3.5% | 1.7% |
| 2011 | 8.2% | 3.6% | 1.5% |
| 2012 | 8.1% | 3.6% | 1.5% |
| 2013 | 8.0% | 3.6% | 1.3% |
| 2014 | 8.2% | 3.9% | 1.4% |
| 2015 | 8.2% | 4.0% | 1.6% |
| 2016 | 7.9% | 4.0% | 1.8% |
| 2017 | 8.1% | 4.3% | 2.8% |
| 2018 | 9.1% | 4.5% | 2.7% |
| 2019 | 8.8% | 3.8% | 2.5% |
| 2020 | 8.8% | 3.9% | 1.6% |
| 2021 | 8.5% | 3.8% | 1.5% |
| 2022 | 8.6% | 3.7% | 1.5% |
| 2023 | 8.1% | 3.4% | 1.5% |
| 2024 | 7.6% | 2.8% | 1.2% |
| 2025 | 7.2% | 2.8% | 1.2% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 10.4% | 9.1% | 1.6% |
| 2007 | 31.8% | 18.4% | 3.8% |
| 2008 | 36.1% | 28.2% | 5.1% |
| 2009 | 7.8% | 22.9% | 3.0% |
| 2010 | 10.3% | 20.9% | 2.9% |
| 2011 | 10.0% | 17.6% | 2.3% |
| 2012 | 11.6% | 14.9% | 2.5% |
| 2013 | 10.3% | 13.9% | 2.1% |
| 2014 | 10.5% | 13.7% | 2.2% |
| 2015 | 12.5% | 14.5% | 2.7% |
| 2016 | 14.6% | 15.6% | 2.9% |
| 2017 | 22.3% | 16.7% | 4.6% |
| 2018 | 22.0% | 16.8% | 4.0% |
| 2019 | 22.4% | 14.2% | 3.9% |
| 2020 | 12.8% | 13.7% | 2.3% |
| 2021 | 12.5% | 13.0% | 2.3% |
| 2022 | 12.5% | 12.8% | 2.3% |
| 2023 | 12.1% | 12.2% | 2.4% |
| 2024 | 8.9% | 8.6% | 1.8% |
| 2025 | 8.5% | 7.1% | 1.8% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Sep 2016)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.